ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
130.568,37
-0,38%
S&P 500
5.718,57
0,28%
US Dollar vs BRL
5,5375
0,00%
Bitcoin
62.992,65
-0,53%
Brent Oil
73,785
0,07%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) Notícias

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN
DataHoraFonteTítuloCódigoCompanhia
20/09/202408:45GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/09/202413:15GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
11/09/202408:00GlobeNewswire Inc.EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety ProfileNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/09/202418:00GlobeNewswire Inc.Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/09/202408:00GlobeNewswire Inc.Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMONASDAQ:REGNRegeneron Pharmaceuticals Inc
05/09/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/09/202417:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/08/202408:00GlobeNewswire Inc.Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/08/202402:00GlobeNewswire Inc.Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/08/202419:45GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for LinvoseltamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/08/202417:05GlobeNewswire Inc.Regeneron Announces Investor Conference Presentations and Oncology Investor WebcastNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/08/202408:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/08/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/08/202407:30GlobeNewswire Inc.Regeneron Reports Second Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/07/202408:30GlobeNewswire Inc.Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative InnovationNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/07/202402:00GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/07/202413:53PR Newswire (US)Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/06/202408:00GlobeNewswire Inc.Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/06/202417:05GlobeNewswire Inc.Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
26/06/202418:30GlobeNewswire Inc.Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/06/202407:10GlobeNewswire Inc.Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/06/202408:00GlobeNewswire Inc.Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)NASDAQ:REGNRegeneron Pharmaceuticals Inc
31/05/202402:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/05/202402:00GlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/05/202408:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/05/202418:03GlobeNewswire Inc.Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
20/05/202415:15GlobeNewswire Inc.Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
17/05/202414:45GlobeNewswire Inc.More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/05/202402:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/05/202407:00GlobeNewswire Inc.Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN

Seu Histórico Recente

OKEX
SUIUSDT
SUI Network
EU
METEX
Metabolic Explorer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados